<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36070099</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9896</ISSN><JournalIssue CitedMedium="Internet"><Volume>258</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Journal of pathology</Title><ISOAbbreviation>J Pathol</ISOAbbreviation></Journal><ArticleTitle>Random forest modelling demonstrates microglial and protein misfolding features to be key phenotypic markers in C9orf72-ALS.</ArticleTitle><Pagination><StartPage>366</StartPage><EndPage>381</EndPage><MedlinePgn>366-381</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/path.6008</ELocationID><Abstract><AbstractText>Clinical heterogeneity observed across patients with amyotrophic lateral sclerosis (ALS) is a known complicating factor in identifying potential therapeutics, even within cohorts with the same mutation, such as C9orf72 hexanucleotide repeat expansions (HREs). Thus, further understanding of pathways underlying this heterogeneity is essential for appropriate ALS trial stratification and the meaningful assessment of clinical outcomes. It has been shown that both inflammation and protein misfolding can influence ALS pathogenesis, such as the manifestation or severity of motor or cognitive symptoms. However, there has yet to be a systematic and quantitative assessment of immunohistochemical markers to interrogate the potential relevance of these pathways in an unbiased manner. To investigate this, we extensively characterised features of commonly used glial activation and protein misfolding stains in thousands of images of post-mortem tissue from a heterogeneous cohort of deeply clinically profiled patients with a C9orf72 HRE. Using a random forest model, we show that microglial staining features are the most accurate classifiers of disease status in our panel and that clinicopathological relationships exist between microglial activation status, TDP-43 pathology, and language dysfunction. Furthermore, we detected spatially resolved changes in fused in sarcoma (FUS) staining, suggesting that liquid-liquid phase shift of this aggregation-prone RNA-binding protein may be important in ALS caused by a C9orf72 HRE. Interestingly, no one feature alone significantly impacted the predictiveness of the model, indicating that the collective examination of all features, or a combination of several features, is what allows the model to be predictive. Our findings provide further support to the hypothesis of dysfunctional immune regulation and proteostasis in the pathogenesis of C9-ALS and provide a framework for digital analysis of commonly used neuropathological stains as a tool to enrich our understanding of clinicopathological relationships within and between cohorts. &#xa9; 2022 The Authors. The Journal of Pathology published by John Wiley &amp; Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. The Journal of Pathology published by John Wiley &amp; Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rifai</LastName><ForeName>Olivia M</ForeName><Initials>OM</Initials><Identifier Source="ORCID">0000-0002-0996-1110</Identifier><AffiliationInfo><Affiliation>Translational Neuroscience PhD Programme, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Longden</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Shaughnessy</LastName><ForeName>Judi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sewell</LastName><ForeName>Michael DE</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Translational Neuroscience PhD Programme, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pate</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>Karina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daniels</LastName><ForeName>Michael Jd</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abrahams</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Human Cognitive Neuroscience-Psychology, School of Philosophy, Psychology and Language Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandran</LastName><ForeName>Siddharthan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McColl</LastName><ForeName>Barry W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sibley</LastName><ForeName>Christopher R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Quantitative Biology, Biochemistry and Biotechnology, School of Biological Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Simons Initiative for the Developing Brain, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gregory</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-3337-4079</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>figshare</DataBankName><AccessionNumberList><AccessionNumber>10.6084/m9.figshare.17145902.v1</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_EX_MR/N50192X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>215454/Z/19/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>108890/Z/15/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Pathol</MedlineTA><NlmUniqueID>0204634</NlmUniqueID><ISSNLinking>0022-3417</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">digital pathology</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">fused in sarcoma (FUS)</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">post-mortem tissue</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>7</Day><Hour>13</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36070099</ArticleId><ArticleId IdType="pmc">PMC9827842</ArticleId><ArticleId IdType="doi">10.1002/path.6008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross&#x2010;sectional study. Lancet Neurol 2012; 11: 323&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature 2016; 539: 197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus&#x2010;Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p&#x2010;linked FTD and ALS. Neuron 2011; 72: 245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis &#x2010; frontotemporal spectrum disorder (ALS&#x2010;FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 2017; 18: 153&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramzon YA, Fratta P, Traynor BJ, et al. The overlapping genetics of amyotrophic lateral sclerosis and frontotemporal dementia. Front Neurosci 2020; 14: 42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7012787</ArticleId><ArticleId IdType="pubmed">32116499</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, DeJesus&#x2010;Hernandez M, Rutherford NJ, et al. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol 2011; 122: 673&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3277860</ArticleId><ArticleId IdType="pubmed">22083254</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama JS, Sirkis DW, Miller BL. C9ORF72 hexanucleotide repeats in behavioral and motor neuron disease: clinical heterogeneity and pathological diversity. Am J Neurodegener Dis 2014; 3: 1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3986607</ArticleId><ArticleId IdType="pubmed">24753999</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourinaris T, Houlden H. C9orf72 and its relevance in parkinsonism and movement disorders: a comprehensive review of the literature. Mov Disord Clin Pract 2018; 5: 575&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6277362</ArticleId><ArticleId IdType="pubmed">30637277</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinagawa S, Naasan G, Karydas AM, et al. Clinicopathological study of patients with C9ORF72&#x2010;associated frontotemporal dementia presenting with delusions. J Geriatr Psychiatry Neurol 2015; 28: 99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4408221</ArticleId><ArticleId IdType="pubmed">25342578</ArticleId></ArticleIdList></Reference><Reference><Citation>Devenney EM, Ahmed RM, Halliday G, et al. Psychiatric disorders in C9orf72 kindreds: study of 1,414 family members. Neurology 2018; 91: e1498&#x2013;e1507.</Citation><ArticleIdList><ArticleId IdType="pubmed">30258023</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Newton J, Niven E, et al. Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener 2014; 15: 9&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">23781974</ArticleId></ArticleIdList></Reference><Reference><Citation>Al&#x2010;Sarraj S, King A, Troakes C, et al. p62 positive, TDP&#x2010;43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72&#x2010;linked FTLD and MND/ALS. Acta Neuropathol 2011; 122: 691&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">22101323</ArticleId></ArticleIdList></Reference><Reference><Citation>King A, Maekawa S, Bodi I, et al. Ubiquitinated, p62 immunopositive cerebellar cortical neuronal inclusions are evident across the spectrum of TDP&#x2010;43 proteinopathies but are only rarely additionally immunopositive for phosphorylation&#x2010;dependent TDP&#x2010;43. Neuropathology 2011; 31: 239&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">21118398</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Frick P, Gr&#xe4;sser FA, et al. Quantitative analysis and clinico&#x2010;pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. Acta Neuropathol 2015; 130: 845&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pubmed">26374446</ArticleId></ArticleIdList></Reference><Reference><Citation>Baborie A, Griffiths TD, Jaros E, et al. Accumulation of dipeptide repeat proteins predates that of TDP&#x2010;43 in frontotemporal lobar degeneration associated with hexanucleotide repeat expansions in C9ORF72 gene. Neuropathol Appl Neurobiol 2015; 41: 601&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4934135</ArticleId><ArticleId IdType="pubmed">25185840</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson Y, Robinson AC, Liu X, et al. Neurodegeneration in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9orf72 is linked to TDP&#x2010;43 pathology and not associated with aggregated forms of dipeptide repeat proteins. Neuropathol Appl Neurobiol 2016; 42: 242&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4832296</ArticleId><ArticleId IdType="pubmed">26538301</ArticleId></ArticleIdList></Reference><Reference><Citation>Troakes C, Maekawa S, Wijesekera L, et al. An MND/ALS phenotype associated with C9orf72 repeat expansion: abundant p62&#x2010;positive, TDP&#x2010;43&#x2010;negative inclusions in cerebral cortex, hippocampus and cerebellum but without associated cognitive decline. Neuropathology 2012; 32: 505&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pubmed">22181065</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory JM, Livesey MR, McDade K, et al. Dysregulation of AMPA receptor subunit expression in sporadic ALS post&#x2010;mortem brain. J Pathol 2020; 250: 67&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6973025</ArticleId><ArticleId IdType="pubmed">31579943</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP&#x2010;43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W, Zhou Y, Tu L, et al. TDP&#x2010;43: from Alzheimer's disease to limbic&#x2010;predominant age&#x2010;related TDP&#x2010;43 encephalopathy. Front Mol Neurosci 2020; 13: 26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7059763</ArticleId><ArticleId IdType="pubmed">32180703</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic&#x2010;predominant age&#x2010;related TDP&#x2010;43 encephalopathy (LATE): consensus working group report. Brain 2019; 142: 1503&#x2013;1527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento C, Di Lorenzo Alho AT, Bazan Concei&#xe7;&#xe3;o Amaral C, et al. Prevalence of transactive response DNA&#x2010;binding protein 43 (TDP&#x2010;43) proteinopathy in cognitively normal older adults: systematic review and meta&#x2010;analysis. Neuropathol Appl Neurobiol 2018; 44: 286&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5902737</ArticleId><ArticleId IdType="pubmed">28793370</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Robinson JL, Malunda JA, et al. Pathological 43&#x2010;kDa transactivation response DNA&#x2010;binding protein in older adults with and without severe mental illness. Arch Neurol 2010; 67: 1238&#x2013;1250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3050578</ArticleId><ArticleId IdType="pubmed">20937952</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyzack GE, Luisier R, Taha DM, et al. Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis. Brain 2019; 142: 2572&#x2013;2580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6735815</ArticleId><ArticleId IdType="pubmed">31368485</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitiprolu M, Jagow C, Tremblay V, et al. A complex of C9ORF72 and p62 uses arginine methylation to eliminate stress granules by autophagy. Nat Commun 2018; 9: 2794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6052026</ArticleId><ArticleId IdType="pubmed">30022074</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanaura H, Kawamukai H, Fujiwara A, et al. C9orf72&#x2010;derived arginine&#x2010;rich poly&#x2010;dipeptides impede phase modifiers. Nat Commun 2021; 12: 5301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8421406</ArticleId><ArticleId IdType="pubmed">34489423</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Wang J, et al. ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight 2017; 2: e89530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333967</ArticleId><ArticleId IdType="pubmed">28289705</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Toledo JB, Van Deerlin VM, et al. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS One 2012; 7: e39216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375234</ArticleId><ArticleId IdType="pubmed">22720079</ArticleId></ArticleIdList></Reference><Reference><Citation>Fyfe I. Do inflammatory profiles explain ALS&#x2010;FTD spectrum? Nat Rev Neurol 2018; 14: 634.</Citation><ArticleIdList><ArticleId IdType="pubmed">30279609</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Allen K, Oei F, et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm 2016; 3: e244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4897985</ArticleId><ArticleId IdType="pubmed">27308305</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckl P, Weydt P, Steinacker P, et al. Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J Neurol Neurosurg Psychiatry 2019; 90: 4&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">30224549</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, et al. ALS clinical trials review: 20&#x2009;years of failure. Are we any closer to registering a new treatment? Front Aging Neurosci 2017; 9: 68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernaus A, Blanco S, Sevilla A. Glia crosstalk in neuroinflammatory diseases. Front Cell Neurosci 2020; 14: 209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7403442</ArticleId><ArticleId IdType="pubmed">32848613</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardenas AM, Sarlls JE, Kwan JY, et al. Pathology of callosal damage in ALS: an ex&#x2010;vivo, 7T diffusion tensor MRI study. Neuroimage Clin 2017; 15: 200&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5429246</ArticleId><ArticleId IdType="pubmed">28529876</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper&#x2010;Knock J, Hewitt C, Highley JR, et al. Clinico&#x2010;pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain 2012; 135: 751&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286332</ArticleId><ArticleId IdType="pubmed">22366792</ArticleId></ArticleIdList></Reference><Reference><Citation>Leighton D, Newton J, Colville S, et al. Clinical audit research and evaluation of motor neuron disease (CARE&#x2010;MND): a national electronic platform for prospective, longitudinal monitoring of MND in Scotland. Amyotroph Lateral Scler Frontotemporal Degener 2019; 20: 242&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">30889975</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, et al. Phases of A beta&#x2010;deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer&#x2010;related changes. Acta Neuropathol 1991; 82: 239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Attems J, Toledo JB, Walker L, et al. Neuropathological consensus criteria for the evaluation of Lewy pathology in post&#x2010;mortem brains: a multi&#x2010;centre study. Acta Neuropathol 2021; 141: 159&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7847437</ArticleId><ArticleId IdType="pubmed">33399945</ArticleId></ArticleIdList></Reference><Reference><Citation>Bankhead P, Loughrey MB, Fern&#xe1;ndez JA, et al. QuPath: open source software for digital pathology image analysis. Sci Rep 2017; 7: 16878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5715110</ArticleId><ArticleId IdType="pubmed">29203879</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory JM, McDade K, Bak TH, et al. Executive, language and fluency dysfunction are markers of localised TDP&#x2010;43 cerebral pathology in non&#x2010;demented ALS. J Neurol Neurosurg Psychiatry 2020; 91: 149&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6996101</ArticleId><ArticleId IdType="pubmed">31515300</ArticleId></ArticleIdList></Reference><Reference><Citation>
GraphPad Prism
, Version 8.0.0. San Diego, California: GraphPad Software. [Accessed 15 July 2022]. Available from: www.graphpad.com.</Citation></Reference><Reference><Citation>
R Core Team
. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing;  [Accessed 15 July 2022]: Available from:Vienna, 2022. https://www.R-project.org/.</Citation></Reference><Reference><Citation>Wickham H. Ggplot2: Elegant Graphics for Data Analysis. Springer&#x2010;Verlag: New York, 2016.</Citation></Reference><Reference><Citation>Berthold MR, Cebron N, Dill F, et al. KNIME: the Konstanz information miner. In Data Analysis, Machine Learning and Applications, Preisach C, Burkhardt H, Schmidt&#x2010;Thieme L, et al. (eds). Springer: Berlin, Heidelberg, 2008; 319&#x2013;326.</Citation></Reference><Reference><Citation>Steinacker P, Barschke P, Otto M. Biomarkers for diseases with TDP&#x2010;43 pathology. Mol Cell Neurosci 2019; 97: 43&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">30399416</ArticleId></ArticleIdList></Reference><Reference><Citation>Haruwaka K, Ikegami A, Tachibana Y, et al. Dual microglia effects on blood brain barrier permeability induced by systemic inflammation. Nat Commun 2019; 10: 5816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6925219</ArticleId><ArticleId IdType="pubmed">31862977</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol 2018; 17: 423&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagemann C, Tyzack GE, Taha DM, et al. Automated and unbiased discrimination of ALS from control tissue at single cell resolution. Brain Pathol 2021; 31: e12937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8412073</ArticleId><ArticleId IdType="pubmed">33576079</ArticleId></ArticleIdList></Reference><Reference><Citation>Neltner JH, Abner EL, Schmitt FA, et al. Digital pathology and image analysis for robust high&#x2010;throughput quantitative assessment of Alzheimer disease neuropathologic changes. J Neuropathol Exp Neurol 2012; 71: 1075&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3511606</ArticleId><ArticleId IdType="pubmed">23147505</ArticleId></ArticleIdList></Reference><Reference><Citation>Vega AR, Chkheidze R, Jarmale V, et al. Deep learning reveals disease&#x2010;specific signatures of white matter pathology in tauopathies. Acta Neuropathol Commun 2021; 9: 170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8529809</ArticleId><ArticleId IdType="pubmed">34674762</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzu P, Blauwendraat C, Heetveld S, et al. C9orf72 is differentially expressed in the central nervous system and myeloid cells and consistently reduced in C9orf72, MAPT and GRN mutation carriers. Acta Neuropathol Commun 2016; 4: 37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4832459</ArticleId><ArticleId IdType="pubmed">27079381</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Rourke JG, Bogdanik L, Y&#xe1;&#xf1;ez A, et al. C9orf72 is required for proper macrophage and microglial function in mice. Science 2016; 351: 1324&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, O'Rourke JG, Y&#xe1;&#xf1;ez A, et al. C9orf72 in myeloid cells suppresses STING&#x2010;induced inflammation. Nature 2020; 585: 96&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484469</ArticleId><ArticleId IdType="pubmed">32814898</ArticleId></ArticleIdList></Reference><Reference><Citation>Lall D, Lorenzini I, Mota TA, et al. C9orf72 deficiency promotes microglial&#x2010;mediated synaptic loss in aging and amyloid accumulation. Neuron 2021; 109: 2275&#x2013;2291.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8298293</ArticleId><ArticleId IdType="pubmed">34133945</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinilla G, Kumar A, Floaters MK, et al. Increased synthesis of pro&#x2010;inflammatory cytokines in C9ORF72 patients. Amyotroph Lateral Scler Frontotemporal Degener 2021; 22: 517&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">33929933</ArticleId></ArticleIdList></Reference><Reference><Citation>Condello C, Yuan P, Schain A, et al. Microglia constitute a barrier that prevents neurotoxic protofibrillar A&#x3b2;42 hotspots around plaques. Nat Commun 2015; 6: 6176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4311408</ArticleId><ArticleId IdType="pubmed">25630253</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown MR, Radford SE, Hewitt EW. Modulation of &#x3b2;&#x2010;amyloid fibril formation in Alzheimer's disease by microglia and infection. Front Mol Neurosci 2020; 13: 609073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7725705</ArticleId><ArticleId IdType="pubmed">33324164</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie M, Liu YU, Zhao S, et al. TREM2 interacts with TDP&#x2010;43 and mediates microglial neuroprotection against TDP&#x2010;43&#x2010;related neurodegeneration. Nat Neurosci 2022; 25: 26&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8741737</ArticleId><ArticleId IdType="pubmed">34916658</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C&#x2010;H, Davidson S, Harapas CR, et al. TDP&#x2010;43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS. Cell 2020; 183: 636&#x2013;649.e18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7599077</ArticleId><ArticleId IdType="pubmed">33031745</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Bell S, et al. TDP&#x2010;43 activates microglia through NF&#x2010;&#x3ba;B and NLRP3 inflammasome. Exp Neurol 2015; 273: 24&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">26222336</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JR, Donnelly CJ. RNA modulates physiological and neuropathological protein phase transitions. Neuron 2021; 109: 2663&#x2013;2681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8434763</ArticleId><ArticleId IdType="pubmed">34297914</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphrey J, Birsa N, Milioto C, et al. FUS ALS&#x2010;causative mutations impair FUS autoregulation and splicing factor networks through intron retention. Nucleic Acids Res 2020; 48: 6889&#x2013;6905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7337901</ArticleId><ArticleId IdType="pubmed">32479602</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook CN, Wu Y, Odeh HM, et al. C9orf72 poly(GR) aggregation induces TDP&#x2010;43 proteinopathy. Sci Transl Med 2020; 12: eabb3774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7989020</ArticleId><ArticleId IdType="pubmed">32878979</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue YC, Ng CS, Xiang P, et al. Dysregulation of RNA&#x2010;binding proteins in amyotrophic lateral sclerosis. Front Mol Neurosci 2020; 13: 78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7273501</ArticleId><ArticleId IdType="pubmed">32547363</ArticleId></ArticleIdList></Reference><Reference><Citation>Wobst HJ, Mack KL, Brown DG, et al. The clinical trial landscape in amyotrophic lateral sclerosis&#x2010;past, present, and future. Med Res Rev 2020; 40: 1352&#x2013;1384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7417284</ArticleId><ArticleId IdType="pubmed">32043626</ArticleId></ArticleIdList></Reference><Reference><Citation>
Rifai O.
Random Forest Modelling and Neuropathological Features of a Large Cohort of C9orf72&#x2010;ALS (All Raw Data); 2021. Available from: https://figshare.com/projects/Random_forest_modelling_and_neuropathological_features_of_a_large_cohort_of_C9orf72&#x2010;ALS_all_raw_data_/128222
</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>